⌕
Natera · NTRA · Nasdaq
Tenet 42 · Weak
Compare
$288.48−9.59%At closeTenet 42 · Weak
$288.48−30.61 (−9.59%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
$293.03+4.55 (+1.58%)
After hours: Nov 16, 2026, 7:51 PM ET

Natera (NTRA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Defense WorldNov 16, 2026 · 03:59 ETEARNINGS EXPECTED BY FEB 18
Natera, Inc. $NTRA Stock Sold by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. trimmed its position in Natera, Inc. (NASDAQ: NTRA) by 16.5% in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institu…

● MarketBeatNov 15, 2026 · 14:12 ET
Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029

Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and opportunities to improve r…

● MarketBeatNov 14, 2026 · 04:12 ET
Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera NASDAQ: NTRA CFO Mike Brophy said the company's newly announced $6 billion revenue target for 2029 is achievable with strong execution, as he outlined expectations for its Signatera cancer test and defended the im…

● Seeking AlphaNov 11, 2026 · 13:39 ET
Natera, Inc. (NTRA) Presents at 2026 UBS Global Healthcare Conference Transcript

Natera, Inc. ( NTRA ) 2026 UBS Global Healthcare Conference November 9, 2026 8:00 AM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Douglas Schenkel - UBS Investment Bank, Res…

● Seeking AlphaNov 11, 2026 · 08:08 ET
Natera, Inc. (NTRA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript

Natera, Inc. ( NTRA ) 8th Annual Wolfe Research Healthcare Conference November 10, 2026 12:00 PM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Paige Chamberlain - Wolfe Resea…

● Business WireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) f…

● Zacks Investment ResearchNov 9, 2026 · 14:31 ETEARNINGS EXPECTED BY FEB 18
Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook

NTRA targets $6B in revenues by 2029 as Signatera testing surges, reimbursement expands and higher investments support its long-term growth strategy.…

● Zacks Investment ResearchNov 9, 2026 · 09:51 ETEARNINGS EXPECTED BY FEB 18
NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up

Natera???s Q3 revenues jump 34.1%, beating estimates, while a wider-than-expected loss and surging oncology test volumes shape its raised 2026 sales outlook.…

● Defense WorldNov 9, 2026 · 04:05 ETEARNINGS EXPECTED BY FEB 18
Natera, Inc. $NTRA Stock Holdings Lessened by Candriam S.C.A.

Candriam S.C.A. cut its stake in shares of Natera, Inc. (NASDAQ: NTRA) by 1.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,048 shares o…

● Defense WorldNov 7, 2026 · 06:07 ET
Natera (NASDAQ:NTRA) Insider Sells $1,401,003.63 in Stock

Natera, Inc. (NASDAQ: NTRA - Get Free Report) insider Solomon Moshkevich sold 3,419 shares of the firm's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $409.77, for a total…

● Defense WorldNov 7, 2026 · 05:04 ET
Natera (NASDAQ:NTRA) CEO Sells $1,565,251.80 in Stock

Natera, Inc. (NASDAQ: NTRA - Get Free Report) CEO Steven Chapman sold 3,801 shares of Natera stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $411.80, for a total transaction…

● Seeking AlphaNov 7, 2026 · 04:54 ETEARNINGS EXPECTED BY FEB 18
Natera, Inc. (NTRA) Q3 2026 Earnings Call Transcript

Natera, Inc. ( NTRA ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of Clinical Diagnostics Al…

● BenzingaNov 6, 2026 · 11:25 ETEARNINGS EXPECTED BY FEB 18
Natera Stock Plummets After Mixed Q3 Financials

Natera Inc. (NASDAQ:NTRA) shares are plunging Friday after reporting mixed third-quarter results, with revenue and guidance beating estimates while the loss per share came in wider than analysts expected. Here's what you…

● MarketBeatNov 6, 2026 · 05:15 ETEARNINGS EXPECTED BY FEB 18
What Natera (NTRA) Said on Its Q3 Earnings Call

Natera NASDAQ: NTRA raised its full-year revenue forecast after reporting a 34% increase in third-quarter revenue, as demand for its cancer-monitoring tests grew and the company announced a change in leadership.…

● Seeking AlphaNov 6, 2026 · 03:15 ETEARNINGS EXPECTED BY FEB 18
Allspring Growth Fund Q3 2026 Performers And Detractors

During the third quarter, Natera achieved record results. Shares advanced during the quarter as Twilio's voice platform was recognized as a backbone for agentic voice agents. Carpenter Technology is benefiting from incre…

● Seeking AlphaNov 6, 2026 · 01:40 ETEARNINGS EXPECTED BY FEB 18
Alger Concentrated Equity ETF Q3 2026 Portfolio Update

The Alger Concentrated Equity ETF underperformed the Russell 1000 Growth Index during the third quarter of 2026. Microsoft Corporation, Natera, Inc., and Meta Platforms Inc were among the top contributors to performance.…

● Business WireNov 5, 2026 · 16:06 ETCOMPANY'S OWN WORDS
Natera Announces Leadership Transition

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Solomon Moshkevich has been appointed Chief Executive Officer and a member of the…

● Business WireNov 5, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 18
Natera Reports Third Quarter 2026 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026. Recent Financial …

● Business WireNov 5, 2026 · 07:00 ET
Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present important new Signatera data at the Society for Immunotherapy of Cance…

● Business WireNov 4, 2026 · 07:00 ET
Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced three peer-reviewed publications in npj Precision Oncology, JAMA Otolaryngology, and A…

● Defense WorldNov 4, 2026 · 04:30 ETEARNINGS EXPECTED BY FEB 18
Aware Super Pty Ltd as trustee of Aware Super Buys 16,018 Shares of Natera, Inc. $NTRA

Aware Super Pty Ltd as trustee of Aware Super bought a new stake in Natera, Inc. (NASDAQ: NTRA) during a recent quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commis…

● Business WireNov 3, 2026 · 07:00 ET
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has received Medicare coverag…

● BenzingaOct 30, 2026 · 07:36 ET
Natera, Shake Shack, eBay And More On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Rob Sechan, founder and managing partner of NewEdge Capital Group, picked eBay Inc. (NASDAQ:EBAY).…

● Business WireOct 27, 2026 · 07:45 ET
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Oncology (ESMO) Congres…

● Business WireOct 26, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidne…

● Business WireOct 18, 2026 · 18:10 ET
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Soci…

● Business WireOct 15, 2026 · 12:46 ET
Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME's Best…

Business Wire · Nov 5, 2026

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 18. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just NTRA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.